Impaired production of burst promoting activity by blood mononuclear cells from chronic uremic patients

Kawano, Yoshifumi; Takaue, Yoichi; Murata, Jun; Abe, Takanori; Matsunaga, Keiko; Hirao, Atsushi; Watanabe, Tsutomu; Hirose, Masao; Ninomiya, Tsuneo; Kawashima, Shuh; Kuroda, Yasuhiro

doi:10.1002/ajh.2830360103

Cited by 5 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The composite nature of BPA can best explain the observation that the burst-enhancing effect derived from monocytes and stimulated T-cells [25] is distinct from that attributable to normal, unstimulated B-cells [26]. The demonstration that the mononuclear cells from patients with chronic uremia have an impaired production of BPA, irrespective of hemodialysis, conflicts with our study [27]. These authors, however, only studied T-cell and monocyte-derived BPA, raising the possibility that the stimulatory activity in our patients may have a different origin.…”

Section: Discussioncontrasting

confidence: 77%

Burst‐promoting activity in the serum of patients with chronic renal failure undergoing long‐term hemodialysis

Randall¹,

Meyer²,

Swanepoel³

et al. 1993

STEM CELLS

View full text Add to dashboard Cite

Anemia in patients with chronic renal failure (CRF) is multifactorial, and while the majority will respond to the paternal administration of recombinant human erythropoietin (r-HuEPO), a role for coexistent plasma inhibitors and stimulators, such as burst-promoting activity (BPA), remains controversial. To evaluate the latter possibility, eight individuals with CRF on long-term hemodialysis, were studied before (mean hemoglobin 58.4 +/- 8.0 g/l and after 12 weeks of r-HuEPO therapy (mean hemoglobin 100.4 +/- 18.3 g/l). In vitro erythroid cultures using erythroid burst forming unit (BFU-E) and erythroid colony forming unit (CFU-E) assays were performed, plating 5 x 10(4) bone marrow mononuclear cells and comparing growth in heat-inactivated autologous serum with AB serum. Using Step III sheep erythropoietin (Connaught Laboratories, Willowdale, Ontario, Canada) (n = 4), mean BFU-E pre-therapy were 89.7 +/- 75.1, CFU-E were 418.5 +/- 150.6, whereas the corresponding figures in AB serum were 2.5 +/- 2.9 and 197 +/- 94.19, p = 0.1, p = 0.01, respectively. Similarly, with r-HuEPO (EPOCONN: Connaught Laboratories, Willowdale, Ontario, Canada) (n = 4), mean BFU-E were 145.25 +/- 103.3 in autologous serum and 31.0 +/- 56.75 in AB serum (p = 0.04). As controls, erythroid progenitors from two normal donors yielded 69 and 61 BFU-E colonies in autologous serum and 103 and 42 in AB serum; the corresponding CFU-E were 52 and 235 versus 136 and 137.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Section: Discussioncontrasting

confidence: 77%

Burst‐promoting activity in the serum of patients with chronic renal failure undergoing long‐term hemodialysis

Randall¹,

Meyer²,

Swanepoel³

et al. 1993

STEM CELLS

View full text Add to dashboard Cite

show abstract

“…We previously reported that a deficiency of erythropoietin is not the sole mechanism in the development of renal anemia. We demonstrated that the burst-promoting activity (BPA) of stimulated peripheral blood mononuclear cells from uremic patients is disturbed, which may explain the occasional poor response to therapy with human recombinant erythropoietin (Epo) (2,3). We also found that the level of M-CSF before the initiation of therapy was inversely correlated with the response to subsequent Epo therapy.…”

Section: Introductionmentioning

confidence: 99%

Effects of monocyte‐macrophage colony‐stimulating factor (M‐CSF) on in vitro erythropoiesis of marrow progenitor cells from patients with renal anemia

Kawano

Takaue

Murata

et al. 1995

European J of Haematology

Self Cite

View full text Add to dashboard Cite

We examined the influence of monocyte‐macrophage colony‐stimulating factor (M‐CSF) on erythropoiesis both in vitro and in vivo in 98 patients with chronic renal failure who were undergoing hemodialysis. Serum levels of M‐CSF and the clinical response to therapy with human recombinant erythropoietin (Epo) were analyzed. The following results were obtained: 1) The serum level of M‐CSF was 6.90 ± 2.41 ng/ml in the patient population (n = 98), but only 2.0 ± 0.3 ng/ml in 10 healthy donors. 2) 41 of the 98 anemic patients were treated with various doses of Epo for 3 months, and the average increase in the blood hemoglobin level during this period was 26.1 ± 12.5 mg/dl/unit of Epo/kg patient's b.w./week. Lower levels of M‐CSF before treatment significantly predicted a better response to subsequent Epo therapy (r = –0.496, p < 0.001). 3) When cultured with a maximally stimulatory amount of Epo (10 IU/ml), the number of marrow early erythroid progenitor cells (burst‐forming unit for erythroid, BFU‐E) in patients was identical to that in normal donors, while the number of late progenitors (colony‐forming unit for erythroid, CFU‐E) was relatively lower in patients. 4) The addition of recombinant M‐CSF to the culture resulted in suppression of erythroid progenitor cell growth in the patient population, but induced enhancement in normal donors. The inhibitory effect of M‐CSF on the patients' cells was not eliminated by the addition of antibodies against interleukin‐1α/β, tumor necrosis factor‐α, or interferon‐α/β/γ. Supernatants from marrow mononuclear cells cultured in the presence of M‐CSF carried this inhibitory effect on marrow CD34+ cells obtained from patients. Together, these results suggest that M‐CSF aggravates a previously existing decreased sensitivity of erythroid progenitor cells to Epo in some patients with renal anemia.

show abstract

Letter to the editor: Rapid modifications of the globin chains synthesized by the BFU‐E cells upon storage

Bhaumik

1991

American J Hematol

View full text Add to dashboard Cite

show abstract

Impaired production of burst promoting activity by blood mononuclear cells from chronic uremic patients

Cited by 5 publications

References 13 publications

Burst‐promoting activity in the serum of patients with chronic renal failure undergoing long‐term hemodialysis

Burst‐promoting activity in the serum of patients with chronic renal failure undergoing long‐term hemodialysis

Effects of monocyte‐macrophage colony‐stimulating factor (M‐CSF) on in vitro erythropoiesis of marrow progenitor cells from patients with renal anemia

Letter to the editor: Rapid modifications of the globin chains synthesized by the BFU‐E cells upon storage

Contact Info

Product

Resources

About